金陵藥業(000919.SZ):宿遷醫院短期內對公司的經營業績無較大影響
格隆匯 10 月 15日丨金陵藥業(000919.SZ)公佈,公司控股子公司南京鼓樓醫院集團宿遷市人民醫院(“宿遷醫院”)新建的宿遷醫院門急診樓和病房綜合樓已竣工並全部投入使用(有關投資建設的具體內容詳見公司於2016年4月22日披露的《關於控股子公司南京鼓樓醫院集團宿遷市人民醫院門急診樓和病房綜合樓項目的公告》。
宿遷醫院門急診樓和病房綜合樓投入使用後,宿遷醫院的整體硬件條件將得以提升改善,醫院的門急診接診能力、住院患者接納人次及對住院患者醫療服務能力均有提高。宿遷醫院的業務收入、利潤將會有一定增長,但短期內對公司的經營業績無較大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.